Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 25, showing 5 Applications out of 121 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s)

16.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
View

17.

ECCT/23/07/01   POWWeR Health Study
    Single arm trial of menstrual cups among economically vulnerable women to reduce Bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices (POWWeR Health Study): A Phase 2 Trial   
Principal Investigator(s)
1. Fredrick Otieno
2. Supriya Dinesh Mehta
Site(s) in Kenya
Nyanza Reproductive Health Society
 
View

18.

ECCT/23/06/09   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Walter Otieno
2. Videlis Nduba
Site(s) in Kenya
1. Kombewa Clinical research Centre (Kisumu county)
2. KEMRI, Siaya Clinical Research Annex (Kisumu county)
 
View

19.

ECCT/23/06/08   TSCV3000
    Age-descending, randomized, placebo-controlled Phase 2 trial in three sites in sub-Saharan Africa to assess the safety and immunogenicity of a parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) versus placebo   
Principal Investigator(s)
1. RICHARD ONYANDO OMORE
Site(s) in Kenya
1. SIAYA COUNTY REFERRAL HOSPITAL (Siaya county)
2. ST. ELIZABETH LWAK HOSPITAL (Siaya county)
 
View

20.

ECCT/23/06/02   IMAGINE-TBM
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM).   
Principal Investigator(s)
1. Deborah Chepng\'eno Langat
Site(s) in Kenya
KEMRI/WRP CRC
 
View